Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 259

1.

Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors.

Maldonado AR, Klanke C, Jegga AG, Aronow BJ, Mahller YY, Cripe TP, Crombleholme TM.

J Gene Med. 2010 Jul;12(7):613-23. doi: 10.1002/jgm.1479.

PMID:
20603890
2.

Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model.

Mahller YY, Vaikunth SS, Currier MA, Miller SJ, Ripberger MC, Hsu YH, Mehrian-Shai R, Collins MH, Crombleholme TM, Ratner N, Cripe TP.

Mol Ther. 2007 Feb;15(2):279-86.

3.

Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants.

Mahller YY, Rangwala F, Ratner N, Cripe TP.

Pediatr Blood Cancer. 2006 Jun;46(7):745-54.

PMID:
16124003
4.

Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors.

Mahller YY, Vaikunth SS, Ripberger MC, Baird WH, Saeki Y, Cancelas JA, Crombleholme TM, Cripe TP.

Cancer Res. 2008 Feb 15;68(4):1170-9. doi: 10.1158/0008-5472.CAN-07-2734.

5.

Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.

Yoo JY, Hurwitz BS, Bolyard C, Yu JG, Zhang J, Selvendiran K, Rath KS, He S, Bailey Z, Eaves D, Cripe TP, Parris DS, Caligiuri MA, Yu J, Old M, Kaur B.

Clin Cancer Res. 2014 Jul 15;20(14):3787-98. doi: 10.1158/1078-0432.CCR-14-0553. Epub 2014 May 9.

6.

Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus.

Kubo S, Kawasaki Y, Yamaoka N, Tagawa M, Kasahara N, Terada N, Okamura H.

J Gene Med. 2010 Aug;12(8):681-92. doi: 10.1002/jgm.1486.

7.

Molecular analysis of human cancer cells infected by an oncolytic HSV-1 reveals multiple upregulated cellular genes and a role for SOCS1 in virus replication.

Mahller YY, Sakthivel B, Baird WH, Aronow BJ, Hsu YH, Cripe TP, Mehrian-Shai R.

Cancer Gene Ther. 2008 Nov;15(11):733-41. doi: 10.1038/cgt.2008.40. Epub 2008 Jun 13.

8.

Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1.

Gaston DC, Odom CI, Li L, Markert JM, Roth JC, Cassady KA, Whitley RJ, Parker JN.

PLoS One. 2013 Nov 27;8(11):e81768. doi: 10.1371/journal.pone.0081768. eCollection 2013.

9.

HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy.

Li H, Nakashima H, Decklever TD, Nace RA, Russell SJ.

Cancer Gene Ther. 2013 Aug;20(8):478-85. doi: 10.1038/cgt.2013.43. Epub 2013 Jul 19.

10.

Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.

Antoszczyk S, Spyra M, Mautner VF, Kurtz A, Stemmer-Rachamimov AO, Martuza RL, Rabkin SD.

Neuro Oncol. 2014 Aug;16(8):1057-66. doi: 10.1093/neuonc/not317. Epub 2014 Jan 26.

11.

MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.

Lee CY, Rennie PS, Jia WW.

Clin Cancer Res. 2009 Aug 15;15(16):5126-35. doi: 10.1158/1078-0432.CCR-09-0051. Epub 2009 Aug 11.

12.

Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.

Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza RL, Kurtz A, Rabkin SD.

Clin Cancer Res. 2006 Nov 15;12(22):6791-9.

13.

The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy.

Miao L, Fraefel C, Sia KC, Newman JP, Mohamed-Bashir SA, Ng WH, Lam PY.

Br J Cancer. 2014 Jan 7;110(1):94-106. doi: 10.1038/bjc.2013.692. Epub 2013 Nov 5.

14.

Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.

Yoo JY, Pradarelli J, Haseley A, Wojton J, Kaka A, Bratasz A, Alvarez-Breckenridge CA, Yu JG, Powell K, Mazar AP, Teknos TN, Chiocca EA, Glorioso JC, Old M, Kaur B.

Clin Cancer Res. 2012 Sep 15;18(18):4931-41. Epub 2012 Jul 2.

15.

Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors.

Deyle DR, Escobar DZ, Peng KW, Babovic-Vuksanovic D.

Gene. 2015 Jul 1;565(1):140-5. doi: 10.1016/j.gene.2015.04.001. Epub 2015 Apr 2.

PMID:
25843626
16.

Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.

Jackson JD, McMorris AM, Roth JC, Coleman JM, Whitley RJ, Gillespie GY, Carroll SL, Markert JM, Cassady KA.

Gene Ther. 2014 Nov;21(11):984-90. doi: 10.1038/gt.2014.72. Epub 2014 Aug 14.

PMID:
25119379
17.

Oncolytic virus therapy using genetically engineered herpes simplex viruses.

Todo T.

Front Biosci. 2008 Jan 1;13:2060-4. Review.

PMID:
17981691
18.

Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.

Ishida D, Nawa A, Tanino T, Goshima F, Luo CH, Iwaki M, Kajiyama H, Shibata K, Yamamoto E, Ino K, Tsurumi T, Nishiyama Y, Kikkawa F.

Cancer Lett. 2010 Feb 1;288(1):17-27. doi: 10.1016/j.canlet.2009.06.014. Epub 2009 Jul 14.

PMID:
19604626
19.

Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.

Kolodkin-Gal D, Edden Y, Hartshtark Z, Ilan L, Khalaileh A, Pikarsky AJ, Pikarsky E, Rabkin SD, Panet A, Zamir G.

Gene Ther. 2009 Jul;16(7):905-15. doi: 10.1038/gt.2009.44. Epub 2009 May 14.

PMID:
19440231
20.

Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.

Shah AC, Parker JN, Gillespie GY, Lakeman FD, Meleth S, Markert JM, Cassady KA.

Gene Ther. 2007 Jul;14(13):1045-54. Epub 2007 Apr 12.

PMID:
17429445

Supplemental Content

Support Center